Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 985-997

  Zeng, Qin ^a   Han, Jianfeng ^a   Zhao, Dong ^a   Gong, Tao ^a   Zhang, Zhirong ^a   Sun, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adenovirus; Anti adenovirus neutralizing antibody; Cationic PEG derivative

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; CAPSID PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; MACROGOL; NEUTRALIZING ANTIBODY; POLYETHYLENEIMINE; CATION; MACROGOL DERIVATIVE;

ADENOVIRUS 5; ARTICLE; BIOSYNTHESIS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; MOLECULAR IMAGING; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; TRANSMISSION ELECTRON MICROSCOPY; VIRAL GENE DELIVERY SYSTEM; ZETA POTENTIAL; ADENOVIRUS; CELL STRAIN HEK293; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY; SERODIAGNOSIS; TUMOR CELL LINE;

ADENOVIRIDAE; COXSACKIEVIRUS;

ADENOVIRIDAE; ANTIBODIES, NEUTRALIZING; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; HEK293 CELLS; HUMANS; NEUTRALIZATION TESTS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TRANSFECTION;

EID: 84862313214     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S27526     Document Type: Article

References (60)

1. Haisma HJ, Bellu AR. Pharmacological interventions for improving adenovirus usage in gene therapy. Mol Pharm. 2011;8(1):50-55.
2. Matthews QL. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm. 2011;8(1):3-11.
3. Renteria SS, Clemens CC, Croyle MA. Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices. Vaccine. 2010;28(9):2137-2148.
4. Gene therapy clinical trials worldwide [database on the Internet]. J Gene Med. Available from: http://www.wiley.com//legacy/wileychi/genmed/ clinical/. Accessed January 25, 2011.
5. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther. 1999;1(4):500-509.
6. Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009;2:115-122.
7. Singh R, Kostarelos K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol. 2009;27(4):220-229.
8. Wu TL, Ertl HC. Immune barriers to successful gene therapy. Trends Mol Med. 2009;15(1):32-39.
9. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem. 2009;108(4):778-790.
10. Zhong Z, Han J, Wan Y, Zhang Z, Sun X. Anionic liposomes enhance and prolong adenovirus-mediated gene expression in airway epithelia in vitro and in vivo. Mol Pharm. 2011;8(3):673-682.
11. Sun C, Zhang Y, Feng L, et al. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine. 2011;29(22):3837-3841.
12. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010; 28(4):950-957.
13. Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol. 2010;82(3):407-414.
14. Singh R, Tian B, Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J. 2008;22(9):3389-3402.
15. Eto Y, Yoshioka Y, Ishida T, et al. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull. 2010;33(9):1540-1544.
16. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11(1):66-79.
17. Eto Y, Gao JQ, Sekiguchi F, et al. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol Pharm Bull. 2004;27(6):936-938.
18. Croyle MA, Chirmule N, Zhang Y, Wilson JM. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001;75(10):4792-4801.
19. Kim PH, Sohn JH, Choi JW, et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials. 2011;32(9):2314-2326.
20. Lee GK, Maheshri N, Kaspar B, Schaffer DV. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng. 2005;92(1):24-34.
21. O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10(8):1349-1358.
22. Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm. 2008;354(1-2):3-8.
23. Jung Y, Park HJ, Kim PH, et al. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. J Control Release. 2007;123(2):164-171.
24. Suzuki-Kouyama E, Katayama K, Sakurai F, et al. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials. 2011;32(6):1724-1730.
25. Wortmann A, Vöhringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther. 2008;16(1):154-162.
26. Wang IJ, Jhuang MC, Chen YH, Yeh LK, Liu CY, Young TH. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS One. 2010;5(8):e12085.
27. Fasbender A, Zabner J, Chillón M, et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem. 1997; 272(10):6479-6489.
28. Steel JC, Cavanagh HM, Burton MA, Dingwall DJ, Kalle WH. Modification of liposomal concentration in liposome/adenoviral complexes allows significant protection of adenoviral vectors from neutralising antibody, in vitro. J Virol Methods. 2005;126(1-2):31-36.
29. Dodds E, Piper TA, Murphy SJ, Dickson G. Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J Neurochem. 1999;72(5):2105-2112.
30. Moselhy J, Sarkar S, Chia MC, et al. Evaluation of copolymers of N-isopropylacrylamide and 2-dimethyl(aminoethyl)methacrylate in nonviral and adenoviral vectors for gene delivery to nasopharyngeal carcinoma. Int J Nanomedicine. 2007;2(3):461-478.
31. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100-109.
32. Ahn CH, Chae SY, Bae YH, Kim SW. Synthesis of biodegradable multi-block copolymers of poly(L-lysine) and poly(ethylene glycol) as a non-viral gene carrier. J Control Release. 2004;97(3): 567-574.
33. Liang B, He ML, Xiao ZP, et al. Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Biophys Res Commun. 2008;367(4):874-880.
34. Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release. 2009;134(3):158-168.
35. Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med. 2005;7(5):604-612.
36. Yamashita M, Ino A, Kawabata K, Sakurai F, Mizuguchi H. Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells. Int J Cancer. 2007;121(8): 1690-1696.
37. Kim JS, Lee SH, Cho YS, Choi JJ, Kim YH, Lee JH. Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR). Gynecol Oncol. 2002;85(2):260-265.
38. Koyama Y, Ito T, Matsumoto H, et al. Novel poly(ethylene glycol) derivatives with carboxylic acid pendant groups: synthesis and their protection and enhancing effect on non-viral gene transfection systems. J Biomater Sci Polym Ed. 2003;14(6):515-531.
39. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2(4):302-317.
40. Fisher KD, Seymour LW. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev. 2010;62(2): 240-245.
41. Subr V, Kostka L, Selby-Milic T, et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release. 2009;135(2):152-158.
42. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther. 2007;18(9): 837-848.
43. Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20(9):975-988.
44. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther. 2008;16(7):1276-1282.
45. Kim P-H, Kim TI, Yockman JW, Kim SW, Yun CO. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials. 2010;31(7):1865-1874.
46. Han J, Zhao D, Zhong Z, Zhang Z, Gong T, Sun X. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology. 2010;21(10):105-106.
47. Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C. Polymerenhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009;6(5):1612-1619.
48. Kelkar SA, Pfister KK, Crystal RG, Leopold PL. Cytoplasmic dynein mediates adenovirus binding to microtubules. J Virol. 2004;78(18):10122-10132.
49. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther. 2002;13(1):143-154.
50. Medina-Kauwe, LK. Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug Deliv Rev. 2003;55(11):1485-1496.
51. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med. 2004; 6 Suppl 1:S152-S163.
52. Davis HE, Morgan JR, Yarmush ML. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem. 2002;97(2-3): 159-172.
53. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113(9):1909-1918.
54. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J. 2004;86(2):1234-1242.
55. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752-3756.
56. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target. 2007;15(7-8):546-551.
57. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release. 1999;60(2-3):149-160.
58. Weiss SI, Sieverling N, Niclasen M, et al. Uronic acids functionalized polyethyleneimine (PEI)-polyethyleneglycol (PEG)-graft-copolymers as novel synthetic gene carriers. Biomaterials. 2006;27(10):2302-2312.
59. Park JW, Mok H, Park TG. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release. 2010;142(2):238-244.
60. Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11(16):1256-1263.